GenSight Biologics S.A

WHO'M
ai
Digital Profiler. Simply click the AI button
CUSIP
F4374K117
SEDOL
BYZVWJ8
CIK
N/A
www.gensight-biologics.com
LEI:
©
FIGI: BBG00D8N3240
SIGHT
GenSight Biologics S.A
GICS: - · Sector: - · Sub-Sector: -
NAME
GenSight Biologics S.A
ISIN
FR0013183985
TICKER
SIGHT
MIC
XPAR
REUTERS
SIGHT.PA
BLOOMBERG
SIGHT FP
BUILD THEMEFOLIO SHARE IDEAS DISCUSS
LEVERAGE INVEST
EN 728x90
Financial Intelligence
360° iHub Crowd iFeed ATH Tracker Index Tracker ETF TF Spicy2 X-Billboard
FOR INVESTORS
FOR TRADERS
Securities Trading Warrants
The X-News Explorer is the ultimate source of information for investors with an affinity for the stock market who want to get a quick and convenient overview of the current news situation of a listed company. Various newswire services are available to you here. If a news alert is displayed, you will find company news that may be of interest to you. This service is provided by BusinessWire.
Wed, 13.11.2024       GenSight Biologics
FR0013183985

Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the submission of the updated regulatory file for LUMEVOQ® gene therapy t...
Read More
GenSight Biologics
Technical Analysis Termsheet Terminal
Permalink
Mon, 28.10.2024       GenSight Biologics
FR0013183985

Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241027820028/en/Figure 1. “A Gradient of Efficacy”: Visual Recovery (CRR from Nadir) Among ND4-LHON Patients (Graphic: Business Wire) GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma c...
Read More
GenSight Biologics
Technical Analysis Termsheet Terminal
Permalink
Thu, 24.10.2024       GenSight Biologics
FR0013183985

Regulatory News: GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position as of September 3...
Read More
GenSight Biologics
Technical Analysis Termsheet Terminal
Permalink
Thu, 17.10.2024       GenSight Biologics
FR0013183985

Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that new scientific data and analyses on the gene therapy LUMEVOQ® will be pre...
Read More
GenSight Biologics
Technical Analysis Termsheet Terminal
Permalink
Mon, 23.09.2024       GenSight Biologics
FR0013183985

Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its interim financial results for the first half of 2024, and provided busi...
Read More
GenSight Biologics
Technical Analysis Termsheet Terminal
Permalink
We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Information on product placements